NCT02346370View on ClinicalTrials.gov

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 10, 2015

Primary Completion Date

August 9, 2016

Study Completion Date

November 14, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

PEGylated recombinant human hyaluronidase PH20

DRUG

Docetaxel

Trial Locations (8)

14642

University of Rochester, Rochester

28112

Levine Cancer Institute, Charlotte

44106

University Hospitals of Cleveland, Cleveland

92024

California Cancer Associates for Research and Excellence (cCare), Encinitas

92093

Moores UCSD Cancer Center, Clinical Trials Office, San Diego

93720

California Cancer Associates for Research and Excellence (cCare), Fresno

03756

Dartmouth-Hitchcock Medical Center, Lebanon

44718-2566

Gabrail Cancer Center Research, Canton

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT02346370 - A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC | Biotech Hunter | Biotech Hunter